EP3900722A1 — Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
Assigned to Bayer AG · Expires 2021-10-27 · 5y expired
What this patent protects
The present invention relates to pharmaceutical compositions and combinations comprising finerenone or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and pecavaptan, or a hydrate, solvate or pharmaceutically acceptable salt thereof or a poly…
USPTO Abstract
The present invention relates to pharmaceutical compositions and combinations comprising finerenone or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and pecavaptan, or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof. The combination can be used for the treatment and/or prevention of cardiovascular and/or renal diseases in humans and other mammals.
Drugs covered by this patent
- Kerendia (FINERENONE) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.